Information for Commercial Organisations - Oxford Cancer: Clinical Positioning Services
Oxford Cancer: Clinical Positioning Services (OCCPS)
OCCPS is an Oxford-based network of scientists and clinicians designed to partner with commercial organisations, and accelerate the clinical development and positioning of novel cancer diagnostic and therapeutic strategies.
For more information please follow this link:
In brief, the focus is on supporting commercial organisations with assets nominated for clinical development who are looking to develop biologically driven studies and/or seeking early positioning advice on the following issues:
- What are the key studies that we should prioritise in order overcome regulatory hurdles and get our novel compound/combination into the clinic?
- What are the different diseases, indications or clinical settings that our asset might be applied to?
- How can we design our early phase clinical studies to ensure better decision-making during further clinical development?
- What companion diagnostics (histopathology, genetic, ctDNA) will complement our clinical studies based on its mechanism of action?
- About Us
- Work With Us: Careers In Trial Management
- Work With Us: Information for Investigators and Commercial Organisations
- Information for Patients, their Families and Carers
- Current Trials
- Trials in Set Up
- CYTOFLOC: Cytosponge™ for post‐chemoradiation surveillance of oesophageal cancer
- FRONTIER: Fluciclovine (18F) imaging of breast cancer
- TARDOX: Targeted chemotherapy using focused ultrasound for liver tumours
- CAMELLIA: Anti-CD47 antibody terapy in relapsed/refractory Haematological Malignancies
- ATOM: Atovaquone as Tumour HypOxia Modifier
- 6MP: A Phase II Clinical Trial in Patients with BRCA Defective Tumours
- AspECT: A Phase III, Randomised, study of Aspirin and Esomeprazole Chemoprevention in Barrett’s Metaplasia
- BKM120: Palliative thoracic radiotherapy plus BKM120
- CHOP-OR: Study of CHOP with Ofatumumab in Patients with Richter's Syndrome
- COG : Gefitinib for oesophageal cancer progressing after chemotherapy
- DATACAP: Dose Adaptation of Capecitabine Using Mobile Phone Toxicity Monitoring
- DEBIOC: Dual Erb B Inhibition in Oesophago-gastric Cancer
- DOC-MEK: A double-blind randomized phase 2 trial of docetaxel with or without selumetinib in wild-type BRAF advanced melanoma
- EnROL: Conventional versus laproscopic surgery for colorectal cancer within an enhanced programme
- FOXFIRE: An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or liver-predominant metastatic colorectal cancer
- LINES: Eurosarc Trial of Linsitinib in advanced Ewing Sarcoma
- MErCuRIC1: MEK and MET Inhibition in Colorectal Cance
- MPP: Application of mobile phone technology for managing chemotherapy-associated side-effects
- OXO-PCR-01: Oxford Ovarian Cancer Predict Chemotherapy Response 01
- PACMEL: A randomised phase 2 study of paclitaxel with or without GSK1120212 or pazopanib in advanced wt BRAF melanoma
- PemBla: A parallel group phase I/II marker lesion study to assess the safety, tolerability and efficacy of intravenous or intravesical pembrolizumab in intermediate risk recurrent non-muscle invasive bladder cancer
- QUASAR2: Multicentre international study of capecitabine ± bevacizumab as adjuvant treatment of colorectal cancer
- RADVAN: A randomised double blind phase 2 trial of whole brain radiotherapy with or without vandetanib in metastatic melanoma with brain metastases.
- SCOT: Short Course Oncology Treatment - A study of adjuvant chemotherapy in colorectal cancer by the CACTUS and OCTO groups.
- SONATINA: A Phase II Multi-Centre Randomised Controlled Study Of Nelfinavir Addition to Radiotherapy Treatment In Neo-Adjuvant Therapy for Rectal Cancer.
- SPARC: SBRT pre-operatively for pancreatic cancer
- VICTOR: Post-treatment stage of a Phase III, randomised, double blind, placebo-controlled study of rofecoxib (VIOXX®) in colorectal cancer patients following potentially curative therapy.
- WBRT: Whole Brain Radiotherapy following local treatment of intracranial metastases of melanoma – A randomised Phase III trial.
- RHYTHM-1: Modulation of Radiotherapy according to HYpoxia: exploiting changes in the Tumour Microenvironment to improve outcome in rectal cancer
- ART: Anal squamous cell carcinoma: Investigation of functional imaging during chemoRadioTherapy
- SCALOP-2: Systemic therapy and Chemoradiation in Advanced Localised Pancreatic cancer–2